Acta Scientific Medical Sciences (ISSN: 2582-0931)

Short Communication Volume 4 Issue 6

Remdesivir as Reposition Drugs for Novel Coronavirus SARS-COV-2 Emergence

Rabi Dayal Singh* and Mangal Dayal Singh

Department of Pharmacology, Maulana Abul Kalam Azad University of Technology, India

*Corresponding Author: Rabi Dayal Singh, Department of Pharmacology, Maulana Abul Kalam Azad University of Technology, India.

Received: May 04, 2020; Published: May 31, 2020


COVID-19 has as of late caused a worldwide wellbeing emergency and a powerful interventional treatment is earnestly needed [1]. SARS-CoV-2 RNA-subordinate RNA polymerase (RdRp) gives a promising however testing drug focus because of its inherent editing exoribonuclease (ExoN) function [2]. Nucleoside triphosphate (NTP) analogs added to the developing RNA chain ought to as far as anyone knows end viral RNA replication, yet ExoN can divide the fused mixes and neutralize their viability. Remdesivir focusing on SARS-CoV-2 RdRp applies high medication viability in vitro and in vivo [3].



  1. WHO, Coronavirus disease 2019 (COVID-19): Situation Report - 23, Covid-19 Situational Reports (2019).
  2. Samuel B. “Medical microbiology”. The University of Texas Medical Branch at Galveston-Tx, USA (1996).
  3. Li F. “Structure, Function, and Evolution of Coronavirus Spike Proteins”. Annual Review of Virology 3.1 (2016): 237-261.
  4. Hilgenfeld R and Peiris M. “From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses”. Antiviral Research 100 (2013): 286-295.
  5. Wu F., et al. “A new coronavirus associated with human respiratory disease in China”. Nature 579 (2020): 265-269.
  6. Zhou P., et al. “A pneumonia outbreak associated with a new coronavirus of probable bat origin”. Nature 579 (2020): 270-273. 
  7. Subissi L., et al. “SARS-CoV ORF1b-encoded nonstructural proteins 12-16: replicative enzymes as antiviral targets”. Antiviral Research 101 (2014): 122-130.
  8. Jordan PC., et al. “Nucleosides for the treatment of respiratory RNA virus infections”. Antiviral Chemistry and Chemotherapy 26 (2018): 2040206618764483. 
  9. Sheahan TP., et al. “Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses”. Science Translational Medicine 9 (2017). 
  10. Agostini ML., et al. “Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease”. mBio 9 (2018).
  11. Gordon CJ., et al. “The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus”. Journal of Biological Chemistry (2020).
  12. Kupferschmidt K and Cohen J. “Race to find COVID-19 treatments accelerates”. Science 367 (2020): 1412-1413.
  13. Ko WC., et al. “Arguments in favour of remdesivir for treating SARS-CoV-2 infections”. The International Journal of Antimicrobial Agents (2020): 105933.
  14. Cao YC., et al. “Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence”. Travel Medicine and Infectious Disease (2020): 101647.
  15. Ahn DG., et al. “Biochemical characterization of a recombinant SARS coronavirus nsp12RNA-dependent RNA polymerase capable of copying viral RNA templates”. Archives of Virology 157 (2012): 2095-2104.
  16. Subissi L., et al. “One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities”. Proceedings of the National Academy of Sciences of the United States of America 111 (2014): E3900-3909.
  17. Gao Y., et al. “Structure of the RNA-dependent RNA polymerase from COVID-19 virus”. Science 7498 (2020).


Citation: Rabi Dayal Singh and Mangal Dayal Singh. “Remdesivir as Reposition Drugs for Novel Coronavirus SARS-COV-2 Emergence". Acta Scientific Medical Sciences 4.6 (2020): 147-148.


Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US